Clinical Assessment: 57-year-old woman with antibiotic-refractory ankle/foot arthritis post-Lyme, renal + hepatic polycystic disease, family history of RA

Differential Diagnosis

1. Antibiotic-Refractory (Post-Infectious) Lyme Arthritis - Most Likely Primary Diagnosis

• Onset temporally linked to erythema migrans (confirmed Lyme exposure)
• Episodic, oligoarticular arthritis of a large joint (ankle), asymmetric
• No response to oral doxycycline OR IV antibiotics
• Episodes lasting months with incomplete resolution - matching the described natural history of waxing-and-waning proliferative synovitis

2. RA Triggered/Unmasked by Lyme Infection

• Ankle + foot involvement (RA commonly affects small joints of the foot/ankle)
• Incomplete resolution between episodes (progressive course typical of RA)
• First-degree family history of RA
• Systemic autoimmune predisposition

3. Reactive Arthritis (post-Lyme or other trigger)

4. Seronegative Spondyloarthropathy

5. Crystal Arthropathy (Gout or Pseudogout)

• Serum uric acid, synovial fluid polarized light microscopy

6. Coinfection / Reactivation

7. Viral Arthritis (Parvovirus B19, Hepatitis C, others)

8. Septic Arthritis (always exclude acutely)

Recommended Workup

Treatment Plan

Core principle: No further antibiotics are indicated

The NSAID constraint: Critical in this patient

• NSAIDs reduce renal prostaglandin-mediated vasodilation, reducing GFR - especially dangerous in polycystic kidney disease
• NSAIDs have hepatotoxic potential in hepatic disease
• Standard first-line therapy for post-antibiotic Lyme arthritis (NSAIDs) must be completely avoided

Step-by-step Treatment Algorithm

• Mechanism: modulates innate immunity, reduces TLR-mediated cytokine signaling
• Well-tolerated in renal/hepatic disease (no renal or hepatic dosing contraindications at normal doses; monitor for retinal toxicity)
• Evidence: recommended by Steere et al. (Rheumatology 2-Volume Set) and Firestein & Kelley as first DMARD; The Rheumatologist experts confirm its use
• Duration: 6-12 months only (unlike RA, post-infectious Lyme arthritis resolves and long-term DMARD is not needed)

• MTX 10-20 mg/week with folate supplementation
• Renal caution: MTX is renally cleared; dose reduction required in reduced GFR. Regular renal function monitoring mandatory. Avoid if GFR < 30 mL/min
• Hepatic caution: MTX is hepatotoxic; baseline liver biopsy consideration if significant hepatic cysts/fibrosis; monitor LFTs regularly. Polycystic liver disease with preserved hepatocyte function is less of a contraindication than cirrhosis, but requires close monitoring
• Evidence: "Methotrexate has been used successfully in some cases" - Red Book 2021; listed explicitly by Steere in Rheumatology 2-Volume Set, p. 2095

• If HCQ and/or MTX fail
• "TNF inhibitors have been used for post-infectious Lyme arthritis" - Rheumatology 2-Volume Set (Elsevier 2022), p. 2095
• Generally well-tolerated renally; hepatic function monitoring needed
• Screen for TB and hepatitis B before starting

• Reserved for severe, disabling, or refractory cases unresponsive to DMARDs
• "Arthroscopic synovectomy is required rarely for disabling or refractory cases" - Red Book 2021, p. 782
• Synovial tissue must be removed down to the cartilage interface; physical therapy for flexibility recovery is needed afterward
• Rheumatology 2-Volume Set, p. 2096-2097

Pain Management (NSAIDs contraindicated)

Monitoring Plan

• LFTs and creatinine/GFR every 3 months (MTX or biologic)
• Eye exam annually (HCQ - Humphrey visual field + SD-OCT)
• Lyme Western blot - do not repeat serially (IgG persists for years regardless of treatment response; not a useful follow-up marker)
• Synovial fluid aspiration at each significant flare

Summary

• Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set, pp. 2485-2490 (Lyme Arthritis and Musculoskeletal manifestations)
• Rheumatology, 2-Volume Set (Elsevier 2022), pp. 2093-2107 (Steere on Lyme Arthritis treatment algorithm)
• Goldman-Cecil Medicine, pp. 2074-2078 (Chronic Lyme Arthritis)
• Red Book 2021, pp. 781-782 (Antibiotic-refractory Lyme Arthritis management)
• IDSA/AAN/ACR 2020 Lyme Disease Clinical Practice Guidelines - No further antibiotics for post-antibiotic Lyme arthritis; DMARDs recommended

What the Imaging Findings Tell You - A Pattern Recognition Issue

Revised Diagnostic Priority

• Reactive arthritis (post-infectious SpA, triggered by Lyme) - most likely given the sequence of events
• Psoriatic arthritis (check skin/nails carefully, even subtle scalp involvement)
• Undifferentiated peripheral SpA

• HLA-B27 (positive in ~70-80% of reactive arthritis)
• Sacroiliac joint MRI (assess for axial involvement)
• X-ray of calcaneus/foot (enthesophytes, erosions)
• Skin and nail exam (psoriasis)
• Anterior uveitis history
• GI symptoms / IBD screening (enteropathic arthritis)

Treatment Plan Tailored to These Findings

Constraint recap: No NSAIDs (renal + hepatic polycystic disease)

Step 1 - Local Treatment: Ultrasound-Guided Corticosteroid Injection

• Ultrasound-guided triamcinolone acetonide (20 mg) injection at the plantar fascial origin on the calcaneus
• Separate US-guided injection into the talonavicular joint (triamcinolone 10-20 mg)
• Periarticular subcutaneous corticosteroid (very low-dose, 5 mg triamcinolone) into the inflamed subcutaneous tissue is an option if swelling is prominent and localized

Step 2 - Physical Therapy and Offloading (Start Immediately, Concurrent with Step 1)

• Custom orthotic insoles with heel cushioning and arch support - distributes load away from the plantar fascial origin and calcaneal enthesis
• Night splint for plantar fasciitis (holds the ankle in slight dorsiflexion, preventing fascia contracture overnight)
• Stretching program: Achilles and plantar fascia eccentric stretching (Alfredson protocol modified for the foot)
• Partial weight-bearing or walking boot/CAM walker during acute flares to offload the calcaneus
• Cold therapy for acute inflammation (ice packs 15-20 min, 2-3x/day) - safe in all patients

Step 3 - Systemic DMARD (Commence Promptly)

Option A - Sulfasalazine (preferred first DMARD for peripheral SpA + enthesitis)

• Dose: Start 500 mg/day, titrate to 2-3 g/day over 4 weeks
• SpA evidence: Sulfasalazine is effective for peripheral joints and enthesitis in reactive arthritis and peripheral SpA
• Renal: Dose reduce if GFR 30-60 mL/min; avoid if GFR <30
• Hepatic: Monitor LFTs; use with caution in hepatic impairment but generally well-tolerated in polycystic liver disease with preserved synthetic function
• Advantage over MTX: Less hepatotoxic than methotrexate

Option B - Hydroxychloroquine 200-400 mg/day

• Already discussed - safe profile, less potent for enthesitis but reasonable for joint inflammation
• Can be combined with sulfasalazine

Option C - Methotrexate 10-15 mg/week

• Effective for peripheral SpA and psoriatic arthritis with enthesitis
• Caution: Renal and hepatic monitoring mandatory (as previously discussed)
• Prefer sulfasalazine first given the hepatic/renal constraints

Step 4 - Biologic Therapy if Steps 1-3 Fail (Escalation at 3 months)

TNF inhibitor - First choice biologic

• Etanercept (subcutaneous, 50 mg/week or 25 mg twice weekly)
• Adalimumab (40 mg every 2 weeks)
• Evidence: Anti-TNF agents reverse calcaneal/entheseal BME on MRI in SpA. TNF-alpha is the pivotal cytokine at the enthesis. Both etanercept and adalimumab are approved for peripheral SpA and reactive arthritis-like presentations
• Renal/hepatic: No dose adjustment needed for renal or hepatic polycystic disease; neither agent is renally cleared or hepatotoxic at standard doses
• Screen for TB (Quantiferon/IGRA), hepatitis B serology before starting

IL-17A inhibitor (secukinumab, ixekizumab) - Alternative biologic

• Particularly effective for enthesitis in SpA (BME resolution demonstrated on MRI)
• IL-17 is a key driver of enthesitis in SpA alongside TNF
• Safe renally; monitor LFTs
• [Harrison SR, Marzo-Ortega H. Ixekizumab for axial SpA. Expert Rev Clin Immunol 2021, PMID 34407705]

Step 5 - Extracorporeal Shock Wave Therapy (ESWT) for Plantar Fasciitis

• ESWT is an evidence-based, non-pharmacological treatment for chronic plantar fasciitis
• Particularly important in this patient given NSAID contraindication
• Calcaneal BME on MRI predicts good response to ESWT - one study found calcaneal BME was the strongest predictor of satisfactory clinical outcome after ESWT in plantar fasciitis (PMID 11036844)
• Protocol: 3 sessions at weekly intervals, 2000 impulses each, 0.12-0.25 mJ/mm²
• No systemic side effects - ideal for this patient

Step 6 - Management of Calcaneal BME Specifically

• Bisphosphonates (ibandronate, zoledronate) have been used for BME syndromes refractory to anti-inflammatory treatment in some protocols - evidence is modest but they may reduce osteoclast activity and BME progression
• Renal caution: Zoledronate requires GFR > 35 mL/min; ibandronate GFR > 30 mL/min - monitor closely in polycystic kidney disease
• Denosumab is an alternative RANKL inhibitor (does not require renal dose adjustment) that reduces BME and bone erosion

Summary Treatment Algorithm

IMMEDIATE:
├── US-guided corticosteroid injection (plantar enthesis + talonavicular joint)
├── Custom orthotics + night splint + physiotherapy
└── Initiate sulfasalazine (500 mg → 2-3 g/day)

SHORT-TERM (4-12 weeks):
├── Add hydroxychloroquine if insufficient response
├── ESWT course (3 sessions) for plantar fasciitis/calcaneal enthesitis
└── HLA-B27, SI joint MRI, skin/nail exam - confirm SpA subtype

MEDIUM-TERM (3 months - if DMARDs insufficient):
├── TNF inhibitor (etanercept or adalimumab) - first choice
│   or IL-17 inhibitor (secukinumab)
└── Follow-up MRI calcaneus/foot to assess BME response

LONG-TERM:
├── If biologic achieves BME resolution → continue 1-2 years, then taper
├── Ongoing physiotherapy and orthotics
└── If BME refractory → consider bisphosphonate/denosumab adjunct

Key Points Specific to This Patient

1. NSAIDs cannot be used - the escalation to DMARDs/biologics must happen sooner than in a typical SpA patient. Do not delay biologics if Step 3 fails.
2. Calcaneal BME on MRI is a structural damage warning sign - it predicts erosive progression if inflammation is not controlled. Early aggressive treatment is justified.
3. The diagnosis may have shifted from post-Lyme arthritis to SpA - enthesitis is not a Lyme feature; this patient may have Lyme-triggered reactive/undifferentiated SpA. HLA-B27 testing is now priority.
4. Analgesia: Acetaminophen/paracetamol max 2 g/day (hepatic polycystic disease) + tramadol cautiously (renal-adjusted dosing). No NSAIDs, no COX-2 inhibitors.
5. Avoid periarticular steroid in the plantar fascia substance directly (risk of fat pad atrophy/fascia rupture); target the entheseal insertion under ultrasound guidance.